DEFR14A: TransCode Therapeutics Seeks Stockholder Approval for Reverse Stock Split and Incentive Plan Amendment

TransCode Therapeutics is asking stockholders to approve a reverse stock split and an amendment to its stock option and incentive plan at the upcoming annual meeting.

Summary

• TransCode Therapeutics is holding its 2024 Annual Meeting of Stockholders on June 13, 2024, to vote on several key proposals.
• The proposals include the election of four directors, an amendment to the company's 2021 Stock Option and Incentive Plan to increase the number of shares available for issuance by 3,000,000, and the ratification of WithumSmith+Brown, PC as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
• A significant proposal involves authorizing the Board of Directors to effect a reverse stock split of the company's outstanding common stock at a ratio ranging from 1-for-2 to 1-for-40.
• The Board seeks the flexibility to determine the exact ratio within this range without further stockholder approval.
• Another proposal asks stockholders to approve adjourning the Annual Meeting to a later date if necessary to solicit additional proxies for the approval of the stock option plan amendment and the reverse stock split.
• The company's Board of Directors recommends voting in favor of all proposals.
• The record date for determining stockholders eligible to vote at the Annual Meeting was April 22, 2024.
• The company is facing potential delisting from the Nasdaq Capital Market due to not meeting the minimum bid price requirement of $1.00 per share.
• The company has requested a hearing before a Nasdaq Hearing Panel to appeal the Nasdaq staff's delisting determination, which is scheduled for June 25, 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is taking proactive steps to address its stock price and incentivize employees, it faces the risk of delisting and potential negative impacts from the reverse stock split. The sentiment is neutral overall, reflecting both challenges and potential solutions.

Positives

• The proposed reverse stock split aims to increase the per share market price of the common stock to meet Nasdaq's minimum bid price requirements, which could encourage increased investor interest.
• The increase in shares available under the 2021 Stock Option and Incentive Plan is intended to attract, retain, and motivate key personnel.
• The Board is committed to creating a diverse board of directors.
• The company has adopted a Compensation Recovery Policy to recover incentive-based compensation from executive officers in the event of a financial restatement.

Negatives

• The company is at risk of being delisted from the Nasdaq Capital Market if it cannot regain compliance with the minimum bid price requirement.
• The reverse stock split may not increase the price of the common stock over the long term.
• The reverse stock split could decrease the liquidity of the common stock.
• The reverse stock split may result in some stockholders owning odd lots that may be more difficult to sell or require greater transaction costs per share to sell.
• The reverse stock split may lead to a decrease in the company's overall market capitalization.

Risks

• Failure to regain compliance with Nasdaq's minimum bid price requirement could result in delisting.
• The reverse stock split may not achieve the desired increase in stock price or maintain it over time.
• Market conditions and company performance could negatively impact the stock price, regardless of the reverse stock split.
• The company's future success depends on its ability to attract, develop, motivate, and retain leading scientific and technical personnel.

Future Outlook

The company aims to increase its stock price to meet Nasdaq's requirements and attract a broader range of investors. The company may use authorized shares in connection with future acquisitions.

Management Comments

• Thomas A. Fitzgerald, Interim Chief Executive Officer and Chief Financial Officer, invites stockholders to attend the 2024 Annual Meeting and encourages them to vote their shares by proxy.
• The Board believes that the Reverse Stock Split, if necessary, is the best option to meet the criteria to satisfy the minimum per share bid price requirement for continued listing on The Nasdaq Capital Market.

Industry Context

Many biotechnology companies face challenges in maintaining stock prices above the minimum requirements for listing on major exchanges, especially during periods of market volatility. Reverse stock splits are a common strategy employed to address this issue.

Comparison to Industry Standards

• Reverse stock splits are a relatively common tactic for companies facing delisting from exchanges like Nasdaq, with companies such as Ligand Pharmaceuticals and Arcturus Therapeutics having previously undertaken similar actions.
• Increasing shares available under equity incentive plans is a standard practice to attract and retain talent, with the specific number of shares varying based on company size and industry benchmarks.
• The company's audit fees are within the typical range for publicly traded companies of similar size and complexity, with firms like WithumSmith+Brown, PC being common auditors for smaller public companies.

Management Changes

Corporate Governance

Stakeholder Impact

• Stockholders: Potential dilution from increased share issuance under the incentive plan; potential impact on stock price and liquidity from the reverse stock split.
• Employees: Potential for increased equity compensation and alignment with company performance.
• Customers: No direct impact expected.
• Suppliers: No direct impact expected.
• Creditors: No direct impact expected.

Next Steps

• Stockholders to vote on the proposals outlined in the proxy statement.
• The Board of Directors to determine whether to implement the reverse stock split and at what ratio, if the proposal is approved.
• The company to present its case to the Nasdaq Hearing Panel on June 25, 2024, to appeal the delisting determination.
• The company to file a Current Report on Form 8-K with the SEC within four business days following the Annual Meeting to announce the final voting results.

Key Dates

Keywords

reverse stock split, proxy statement, stock option plan, annual meeting, Nasdaq, directors, compensation, delisting, stockholders, TransCode Therapeutics